Thus, the ability to suppress the activity of both wild-type and ESR1-mutated ERs may constitute a particularly effective therapeutic approach, especially in patients with pre-treated ER+/HER2– breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.